Drug shortage: Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection (BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE, SENSORCAINE MPF, SENSORCAINE)
FDA lists 20 presentations as Current. Availability: Unavailable (9), Available (11). Reason: Other; Demand increase for the drug. Companies: Hospira, Inc., a Pfizer Company, Fresenius Kabi USA, LLC.
- Published by source
- 2018-02-20
- First seen by Reality Radar
- 2026-10-22
- Last verified
- 2026-10-22
Affected
- Manufacturer
- Hospira, Inc., a Pfizer Company
- Products
- Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE SENSORCAINE MPF SENSORCAINE
Whether your exact unit is affected depends on the model, serial number and region in the official notice.
What the official notice says
Risk: Current — Unavailable
Remedy / actions:
- Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay
- Check wholesaler for inventory
Is this affecting you?
Add what you own or use and Reality Radar will tell you when official changes match it — with evidence and next steps.
Sources
- openFDA Drug Shortages Tier A · official published 2018-02-20
Evidence ledger
Every piece of evidence we store is appended to a public hash chain, so later edits are detectable. Anyone can re-verify it.
| Entry | Kind | Observed | Evidence hash | Entry hash |
|---|---|---|---|---|
| #885 | new | 2026-10-22 | d1cde4a31163…2a8d77 | f050dc0ca116…cc70fa |
Chain head: #1076 8ad5adc30b9b…88ce20